PharmaTech Integrates 2022 Track 2
FIT FOR THE FUTURE
Focusing on new therapies and the technology developments required for them to realise their full potential
Welcome and opening remarks
Identifying the next steps to drive forward the potential of oligonucleotides, DNA and RNA based therapeutics
Dave Laffan | Senior Director in Chemical Development | AstraZeneca
Jeske Smink | Head of Drug Substance | Silence Therapeutics plc
Mark Cunningham | Head of Operations | NATA, MRC, UKRI
Juliana Haggerty | Head of Centre of Excellence – Lipid Nanoparticles | CPI
Anna Perdrix Rosell | Founder & Co-CEO | Sixfold Bioscience
Peter Smith | Principal Scientist, New Modalities (Oligonucleotides) | Astrazeneca
ADC… it’s as easy as 1,2,3…4?
The accelerating growth in Antibody Drug Conjugate (ADC) development and commercialisation provides an exciting outlook for targeted therapies – but with four complex, disparate, components to bring together (antibody, toxin-linker, bioconjugation, sterile fill-finish), what does the current partnership model look like, and how must CDMOs evolve to meet future development and manufacturing requirements in this space?
David Molyneux | Business Development Director | Sterling Pharma Solutions
Steven Raw | Director – Chemical Development, Process Chemistry | AstraZeneca
Stewart Mitchell | EVP & Site Head, Deeside | Sterling Pharma Solutions
Dave Simpson | Chief Executive Officer | Iksuda Therapeutics
Addressing the considerable challenges for improving the production of advanced cell and gene therapies.
Nicholas Medcalf | Bioengineering Consultant | Biomatics
Raja Sharif | Founder and Chief Executive Officer | ATMPS Ltd
Stephen Ward | Chief Manufacturing Officer | Cell and Gene Therapy Catapult
Sana Ahmed | Director of Quality by Design | QbDVision
David Johnson | Sales & Marketing Director | 3P Innovation